Digest Network Come funziona
Network
/
Società
Me
Non verificato

Merck

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

31 comunicati stampa

Guarda tutti i comunicati
12/01/2026
Eventi
Industria
Salute
Farmaceutica
Medicina - Varie
Oncologia
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
Fonte
Merck
Emittente
Business Wire
1.00
0
12/01/2026
Eventi
Industria
Salute
Farmaceutica
Medicina - Varie
Oncologia
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
Fonte
Merck
Emittente
Business Wire
1.00
0
22/12/2025
Oncologia
Auto/Automotive
Salute
Sanità
Farmaceutica
Industria
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor
Fonte
Merck
Emittente
Business Wire
1.00
0
24/11/2025
Industria
Attrezzature medico-sanitarie
Salute
Sanità
Medicina - Varie
Farmaceutica
Merck Takes Patient-Directed Approach to Bring Innovation to the Treatment of Rare Neuromuscular Disorder, Generalized Myasthenia Gravis
Fonte
Merck
Emittente
Business Wire
1.00
0
28/10/2025
Merck Partners with Promega to Advance 3-D Cell Drug Discovery Technologies
Fonte
Merck
Emittente
Business Wire
1.00
0
17/10/2025
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT
Fonte
Merck
Emittente
Business Wire
1.00
0
15/10/2025
Merck to Acquire the Chromatography Business of JSR Life Sciences, Expanding Protein A Capabilities and Downstream Portfolio
Fonte
Merck
Emittente
Business Wire
1.00
0
23/09/2025
Merck and Siemens Deepen Strategic Partnership to Accelerate AI and Data-Driven Drug Discovery and Development
Fonte
Merck
Emittente
Business Wire
1.00
0
18/09/2025
Merck Opens Climate-Neutral €150 Million Filter Manufacturing Facility in Ireland
Fonte
Merck
Emittente
Business Wire
1.00
0
17/09/2025
Igiene alimentare
Salute
Sanità
Farmaceutica
Eventi
Industria
Merck to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 2025
Fonte
Merck
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0